Edward Conner
Chief Tech/Sci/R&D Officer bei THIRD HARMONIC BIO, INC.
Vermögen: - $ am 31.03.2024
Profil
Edward R.
Conner is currently the Chief Medical Officer at Third Harmonic Bio, Inc. He previously held positions as the Medical Director at Genentech, Inc. from 2008 to 2013, Senior Medical Director at BioMarin Pharmaceutical, Inc. from 2013 to 2014, Independent Director at Imara, Inc. from 2020 to 2023, Chief Medical Officer & Senior Vice President at Sangamo Therapeutics, Inc. from 2016 to 2019, Vice President-Clinical Development at Ultragenyx Pharmaceutical, Inc. from 2015 to 2016, Division Head-Gene Therapy Medical & Development at Astellas Gene Therapies, Inc. from 2019 to 2021, and Chief Medical Officer at Locanabio, Inc. from 2021 to 2022.
He obtained his undergraduate degree from Duke University and his doctorate degree from The University of California, San Francisco.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
THIRD HARMONIC BIO, INC.
-.--% | 05.01.2024 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Edward Conner
| Unternehmen | Position | Beginn |
|---|---|---|
| THIRD HARMONIC BIO, INC. | Chief Tech/Sci/R&D Officer | 01.06.2022 |
Ehemalige bekannte Positionen von Edward Conner
| Unternehmen | Position | Ende |
|---|---|---|
| IMARA | Director/Board Member | 24.02.2023 |
Locanabio, Inc.
 Locanabio, Inc. Packaged SoftwareTechnology Services Locana, Inc. engages in the provision of ribonucleic acid targeting gene therapy. Its platform technology addresses a wide spectrum of human genetic diseases. It has advanced a powerful modular RNA targeting-effector approach to optimize and advance therapeutic candidates that is distinct from DNA-targeted approaches and nucleic acid-based RNA targeting. The company was founded by Gene Yeo and David Nelles in 2016 and is headquartered in San Diego, CA. | Chief Tech/Sci/R&D Officer | 01.06.2022 |
| AUDENTES THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
| SANGAMO THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 31.05.2019 |
| ULTRAGENYX PHARMACEUTICAL INC. | Corporate Officer/Principal | 01.10.2016 |
Ausbildung von Edward Conner
| Duke University | Undergraduate Degree |
| The University of California, San Francisco | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| SANGAMO THERAPEUTICS, INC. | Health Technology |
| ULTRAGENYX PHARMACEUTICAL INC. | Health Technology |
| THIRD HARMONIC BIO, INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Astellas Gene Therapies, Inc.
 Astellas Gene Therapies, Inc. BiotechnologyHealth Technology Astellas Gene Therapies, Inc. is a biotechnology company, which engages in the development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA. | Health Technology |
Imara, Inc.
 Imara, Inc. Pharmaceuticals: MajorHealth Technology Imara, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel therapeutics to treat patients suffering from hemoglobinopathies. The company was founded by James Gregg McArthur in 2016 and is headquartered in Brookline, MA. | Health Technology |
Locanabio, Inc.
Locanabio, Inc. Packaged SoftwareTechnology Services Locana, Inc. engages in the provision of ribonucleic acid targeting gene therapy. Its platform technology addresses a wide spectrum of human genetic diseases. It has advanced a powerful modular RNA targeting-effector approach to optimize and advance therapeutic candidates that is distinct from DNA-targeted approaches and nucleic acid-based RNA targeting. The company was founded by Gene Yeo and David Nelles in 2016 and is headquartered in San Diego, CA. | Technology Services |
